Update on Dengue Vaccine Developments
Preliminary Results of Sanofi Pasteur's Dengue Vaccine Candidate Phase 3 Trial in Latin America
03 SEPTEMBER 2014– Sanofi Pasteur, the vaccines division of the French pharmaceutical company Sanofi, announced in a press release the preliminary results of a Phase 3 trial of its candidate dengue vaccine conducted in five countries in Latin America.
The press release indicates that the trial showed efficacy of 60.8 percent of reduction of dengue disease cases. It also states that efficacy against serotypes 1, 2, 3, and 4 is 50.3 percent, 42.3 percent, 74.0 percent , 77.7 percent, respectively. Vaccine efficacy was statistically significant for all serotypes. No safety concerns were observed.
DVI welcomes these encouraging preliminary results on the efficacy and safety observed in the Latin American trial and awaits the publication of the full set of data. Once these are publically available, WHO will provide an independent assessment of the study results.